Nirmatrelvir/ritonavir: real world drug-drug interaction management experience.
Expert Rev Anti Infect Ther
; : 1-3, 2024 Aug 22.
Article
em En
| MEDLINE
| ID: mdl-39109469
ABSTRACT
BACKGROUND:
In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions. RESEARCH DESIGN ANDMETHODS:
We analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.RESULTS:
Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.CONCLUSIONS:
This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Expert Rev Anti Infect Ther
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Reino Unido
País de publicação:
Reino Unido